CA3279426A1 - Dpep-1 binding compositions and methods of use - Google Patents

Dpep-1 binding compositions and methods of use

Info

Publication number
CA3279426A1
CA3279426A1 CA3279426A CA3279426A CA3279426A1 CA 3279426 A1 CA3279426 A1 CA 3279426A1 CA 3279426 A CA3279426 A CA 3279426A CA 3279426 A CA3279426 A CA 3279426A CA 3279426 A1 CA3279426 A1 CA 3279426A1
Authority
CA
Canada
Prior art keywords
dpep
methods
binding compositions
binding
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3279426A
Other languages
English (en)
Inventor
Stephen Mark Robbins
Donnal Lorraine Senger
Jennifer Joy Rahn
Saurav Roy Choudhury
Arthur Wing Sze Lau
Daniel Abraham Muruve
Original Assignee
Arch Biopartners Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Biopartners Inc filed Critical Arch Biopartners Inc
Publication of CA3279426A1 publication Critical patent/CA3279426A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/302—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/13—Dipeptidases (3.4.13)
    • C12Y304/13019—Membrane dipeptidase (3.4.13.19)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3279426A 2015-08-11 2016-08-11 Dpep-1 binding compositions and methods of use Pending CA3279426A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562203704P 2015-08-11 2015-08-11
US62/203,704 2015-08-11
US201562264032P 2015-12-07 2015-12-07
US62/264,032 2015-12-07
CA2999800A CA2999800C (en) 2015-08-11 2016-08-11 Dpep-1 binding compositions and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2999800A Division CA2999800C (en) 2015-08-11 2016-08-11 Dpep-1 binding compositions and methods of use

Publications (1)

Publication Number Publication Date
CA3279426A1 true CA3279426A1 (en) 2026-03-02

Family

ID=57983413

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3279426A Pending CA3279426A1 (en) 2015-08-11 2016-08-11 Dpep-1 binding compositions and methods of use
CA2999800A Active CA2999800C (en) 2015-08-11 2016-08-11 Dpep-1 binding compositions and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2999800A Active CA2999800C (en) 2015-08-11 2016-08-11 Dpep-1 binding compositions and methods of use

Country Status (8)

Country Link
US (3) US10493127B2 (enExample)
EP (2) EP4643873A3 (enExample)
JP (3) JP7054674B2 (enExample)
AU (3) AU2016305299B2 (enExample)
CA (2) CA3279426A1 (enExample)
ES (1) ES3057215T3 (enExample)
IL (2) IL305285A (enExample)
WO (1) WO2017025802A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7054674B2 (ja) * 2015-08-11 2022-04-14 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ－１結合組成物および使用の方法
JP7109791B2 (ja) 2016-06-24 2022-08-01 フンダシオン パラ ラ インベスティガシオン ビオメディカ デル オスピタル グレゴリオ マラニョン 敗血症の処置のために用いられるシラスタチン
AU2019386379B2 (en) * 2018-11-30 2025-05-22 Arch Biopartners, Inc. DPEP-1 binding agents and methods of use
KR102730193B1 (ko) * 2020-07-24 2024-11-14 신규철 단일성분의 마이크로구조체 색전물질과 그 색전물질을 이용한 색전술로 시행되는 치료방법
KR102486996B1 (ko) * 2020-09-04 2023-01-10 서울대학교병원 펩타이드 및 이를 포함하는 피부 주름 개선용 조성물 및 대사성 질환 치료용 조성물
IL307413A (en) * 2021-04-08 2023-12-01 Nat Res Council Canada Dpep-1 binding agents and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5629179A (en) 1995-03-17 1997-05-13 Novagen, Inc. Method and kit for making CDNA library
US5698401A (en) 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
US6174687B1 (en) * 1999-02-26 2001-01-16 The Burnham Institute Methods of identifying lung homing molecules using membrane dipeptidase
CA2323071C (en) 1998-03-13 2011-06-21 The Burnham Institute Molecules that home to various selected organs or tissues
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
AU2003254185A1 (en) 2002-07-27 2004-02-16 The Johns Hopkins School Of Medicine Design and synthesis of renal dipeptidase inhibitors
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2006010496A1 (en) * 2004-07-28 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidase 1 (dpep1)
WO2007146188A2 (en) 2006-06-07 2007-12-21 The Board Of Trustees Of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
EP2196212A4 (en) 2007-10-04 2012-01-25 Josai University Corp PREPARATION AND METHOD FOR THE ADMINISTRATION OF A VACCINE AND IONTOPHORESE DEVICE WITH THE PREPARATION
US9216185B2 (en) * 2008-07-11 2015-12-22 Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon Use of cilastatin to reduce nephrotatoxicity of various compounds
WO2010099084A2 (en) 2009-02-27 2010-09-02 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules
WO2011112435A1 (en) 2010-03-09 2011-09-15 Merck Sharp & Dohme Corp. FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2015120536A1 (en) * 2014-02-13 2015-08-20 Arch Cancer Therapeutics, Inc. Peptides that block leukocyte recruitment and methods of use
JP7054674B2 (ja) * 2015-08-11 2022-04-14 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ－１結合組成物および使用の方法
JP7109791B2 (ja) 2016-06-24 2022-08-01 フンダシオン パラ ラ インベスティガシオン ビオメディカ デル オスピタル グレゴリオ マラニョン 敗血症の処置のために用いられるシラスタチン

Also Published As

Publication number Publication date
EP4643873A3 (en) 2026-04-29
AU2021203872B2 (en) 2023-09-21
IL257458B1 (en) 2023-09-01
US10493127B2 (en) 2019-12-03
EP3334459C0 (en) 2025-12-17
EP3334459A1 (en) 2018-06-20
AU2023285759A1 (en) 2024-02-22
AU2021203872A1 (en) 2021-07-08
IL257458B2 (en) 2024-01-01
US12569538B2 (en) 2026-03-10
CA2999800C (en) 2025-12-09
US20170258872A1 (en) 2017-09-14
EP3334459B1 (en) 2025-12-17
AU2016305299B2 (en) 2021-03-11
AU2023285759B2 (en) 2025-11-13
JP2022023215A (ja) 2022-02-07
WO2017025802A1 (en) 2017-02-16
IL305285A (en) 2023-10-01
JP2024050701A (ja) 2024-04-10
EP3334459A4 (en) 2019-04-17
IL257458A (en) 2018-04-30
ES3057215T3 (en) 2026-02-26
US11666631B2 (en) 2023-06-06
US20240108686A1 (en) 2024-04-04
CA2999800A1 (en) 2017-02-16
JP7054674B2 (ja) 2022-04-14
US20200078442A1 (en) 2020-03-12
AU2016305299A1 (en) 2018-04-05
JP2018528263A (ja) 2018-09-27
EP4643873A2 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
EP3288958A4 (en) Compositions of obeticholic acid and methods of use
EP3245291A4 (en) Novel micro-dystrophins and related methods of use
CA3244408A1 (en) Therapeutic compositions, combinations, and methods of use
EP3268018A4 (en) Bacterial compositions and methods of use thereof
EP3279256A4 (en) Resin composition and use of same
EP3194525A4 (en) Proppant compositions and methods of use
EP3097122A4 (en) Binding proteins and methods of use thereof
EP3377070A4 (en) COMPOUNDS AND METHOD FOR THEIR USE
EP3218443A4 (en) Refrigerant compositions and methods of use
EP3116511A4 (en) Compositions of selenoorganic compounds and methods of use thereof
EP3194564A4 (en) Trichoderma compositions and methods of use
EP3166892A4 (en) Scale-inhibition compositions and methods of making and using the same
ZA201804779B (en) Compositions comprising 15-hepe and methods of using the same
EP3253389A4 (en) Apilimod compositions and methods for using same
EP3190886A4 (en) Compositions and methods of use thereof
EP3288379A4 (en) Peptide compositions and methods of use
EP3247365A4 (en) Novel iodophor composition and methods of use
IL257458A (en) dpep-1 binding compositions and methods of use
EP3376862A4 (en) CRYOPRESERVATION COMPOSITIONS AND METHODS OF USE
EP3148651A4 (en) Topical lightening composition and methods of use thereof
EP3113774A4 (en) Compositions of grapiprant and methods for using the same
EP3281981A4 (en) Resin composition and use of same
EP3253396A4 (en) Probiotic compositions and methods of use
EP3256608A4 (en) RNA CONTAINING COMPOSITIONS AND METHODS OF USE
EP3160235A4 (en) Molluscicide compositions and methods of use thereof

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL

Effective date: 20250708

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250708

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250708

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250920

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250920

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250920

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250920

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250922

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20251020

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20260113

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260113

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20260113

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-2-2-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20260302